The FDA has revoked its approval of AstraZeneca’s Evusheld due to the fact that it is not effective against more than 90% of COVID-19 variants currently in circulation in the US. The antibody treatment was previously used as an additional layer of protection against the virus for those with compromised immune systems, such as those undergoing chemotherapy, or organ-transplant patients.
FDA pulls approval of COVID-19 antibody treatment due to inefficacy against variants
